A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
PHASE3CompletedINTERVENTIONAL
Enrollment
636
Participants
Timeline
Start Date
Not specified
Study Completion Date
October 31, 1997
Conditions
Alzheimer DiseaseDementia
Interventions
DRUG
galantamine hydrobromide
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00253201 - A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter